



ASX ANNOUNCEMENT - 31 August 2006

## **ANTI-DIABETES COMPOUND ADVANCES** **TOWARDS HUMAN TRIALS**

Dia-B Tech Limited's anti-diabetes compound ISF402 moved a step closer to human clinical trials after the completion of trials on animals.

The 28-day repeat dose study on 80 rats found that ISF402 is safe, said Dia-B Tech chairman Dr Michael Wooldridge.

"The results of the repeat dose animal toxicology study has indicated no adverse effects at dose levels well above those planned for human clinical trials," he said. "These results show that ISF402 has a good safety profile."

Together with the results of pharmacokinetic studies, which are currently underway, these studies will clear the path for Dia-B to apply for human ethics approval to commence Phase 1 human trials in the last quarter of 2006.

The Phase 1 trial will comprise a single dose trial, with a likely dosing of between 2 and 30mg per kg of body weight. This compares to the recently completed rat trials which used much higher doses of 550mg/kg.

This final animal toxicology study revealed:

- No adverse clinical signs in all treated animals
- Organ weights did not show any significant difference between control and treated groups
- Histopathological analysis did not reveal any abnormalities related to treatment

Final analysis of the results will be available within two weeks.

**For more information, please contact:**

**Ken Smith, CEO**

**Dia-B Tech Limited  
ACN 102 456 048  
Tel: +61 3 8862 6319  
Fax: +61 3 8862 6610  
Mob: 0412 190 908  
[www.dia-btech.com.au](http://www.dia-btech.com.au)**